Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 2097 - 2104 of 12086 results

Energy & Sustainability M&A Activity — November 2022
November 14, 2022| Article| Viewpoint

Energy & Sustainability IP Updates — November 2022
November 14, 2022| Article| Viewpoint

Energy & Sustainability Litigation Updates — November 2022
November 14, 2022| Article| Viewpoint

Energy & Sustainability Event Highlights — November 2022
November 14, 2022| Article| Viewpoint

A Dose of Steroids: Chair Khan's FTC Releases Expansive Policy Statement on Unfair Methods of Competition
November 14, 2022| Blog| Viewpoint

PBM Regulatory Roundup (Fall 2022): State Medicaid Enforcement Efforts Continue As Legislative Activity Slows Down
November 14, 2022| Blog| Viewpoint

How Mintz's San Diego Office Is Working to Dismantle Systemic Racism, Police Brutality
November 14, 2022| News

California Legislative Update Part I: New Requirements for Licensed Health Care Professionals
November 11, 2022| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
